Calcium-sensing receptor: A high-affinity presynaptic target for aminoglycoside-induced weakness

Mark T. Harnett, Wenyan Chen, Stephen Smith

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Administration of aminoglycoside antibiotics can precipitate sudden, profound bouts of weakness that have been attributed to block of presynaptic voltage-activated calcium channels (VACCs) and failure of neuromuscular transmission. This serious adverse drug reaction is more likely in neuromuscular diseases such as myasthenia gravis. The relatively low affinity of VACC for aminoglycosides prompted us to explore alternative mechanisms. We hypothesized that the presynaptic Ca2+-sensing receptor (CaSR) may contribute to aminoglycoside-induced weakness due to its role in modulating synaptic transmission and its sensitivity to aminoglycosides in heterologous expression systems. We have previously shown that presynaptic CaSR controls a non-selective cation channel (NSCC) that regulates nerve terminal excitability and transmitter release. Using direct, electrophysiological recording, we report that neuronal VACCs are inhibited by neomycin (IC50 830 ± 110 μM) at a much lower affinity than CaSR-modulated NSCC currents recorded from acutely isolated presynaptic terminals (synaptosomes; IC50 20 ± 1 μM). Thus, at clinically relevant concentrations, aminoglycoside-induced weakness is likely precipitated by enhanced CaSR activation and subsequent decrease in terminal excitability rather than through direct inhibition of VACCs themselves.

Original languageEnglish (US)
Pages (from-to)502-505
Number of pages4
JournalNeuropharmacology
Volume57
Issue number5-6
DOIs
StatePublished - Oct 2009

Fingerprint

Calcium-Sensing Receptors
Aminoglycosides
Calcium Channels
Inhibitory Concentration 50
Cations
Neuromuscular Diseases
Neomycin
Synaptosomes
Myasthenia Gravis
Presynaptic Terminals
Drug-Related Side Effects and Adverse Reactions
Synaptic Transmission
Anti-Bacterial Agents

Keywords

  • Aminoglycoside
  • Calcium-sensing receptor
  • GPCR
  • Myastheia gravis
  • Nerve terminal
  • VACC

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Calcium-sensing receptor : A high-affinity presynaptic target for aminoglycoside-induced weakness. / Harnett, Mark T.; Chen, Wenyan; Smith, Stephen.

In: Neuropharmacology, Vol. 57, No. 5-6, 10.2009, p. 502-505.

Research output: Contribution to journalArticle

@article{8a9491acd6684c96ae9e967343e455cb,
title = "Calcium-sensing receptor: A high-affinity presynaptic target for aminoglycoside-induced weakness",
abstract = "Administration of aminoglycoside antibiotics can precipitate sudden, profound bouts of weakness that have been attributed to block of presynaptic voltage-activated calcium channels (VACCs) and failure of neuromuscular transmission. This serious adverse drug reaction is more likely in neuromuscular diseases such as myasthenia gravis. The relatively low affinity of VACC for aminoglycosides prompted us to explore alternative mechanisms. We hypothesized that the presynaptic Ca2+-sensing receptor (CaSR) may contribute to aminoglycoside-induced weakness due to its role in modulating synaptic transmission and its sensitivity to aminoglycosides in heterologous expression systems. We have previously shown that presynaptic CaSR controls a non-selective cation channel (NSCC) that regulates nerve terminal excitability and transmitter release. Using direct, electrophysiological recording, we report that neuronal VACCs are inhibited by neomycin (IC50 830 ± 110 μM) at a much lower affinity than CaSR-modulated NSCC currents recorded from acutely isolated presynaptic terminals (synaptosomes; IC50 20 ± 1 μM). Thus, at clinically relevant concentrations, aminoglycoside-induced weakness is likely precipitated by enhanced CaSR activation and subsequent decrease in terminal excitability rather than through direct inhibition of VACCs themselves.",
keywords = "Aminoglycoside, Calcium-sensing receptor, GPCR, Myastheia gravis, Nerve terminal, VACC",
author = "Harnett, {Mark T.} and Wenyan Chen and Stephen Smith",
year = "2009",
month = "10",
doi = "10.1016/j.neuropharm.2009.07.031",
language = "English (US)",
volume = "57",
pages = "502--505",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "Elsevier Limited",
number = "5-6",

}

TY - JOUR

T1 - Calcium-sensing receptor

T2 - A high-affinity presynaptic target for aminoglycoside-induced weakness

AU - Harnett, Mark T.

AU - Chen, Wenyan

AU - Smith, Stephen

PY - 2009/10

Y1 - 2009/10

N2 - Administration of aminoglycoside antibiotics can precipitate sudden, profound bouts of weakness that have been attributed to block of presynaptic voltage-activated calcium channels (VACCs) and failure of neuromuscular transmission. This serious adverse drug reaction is more likely in neuromuscular diseases such as myasthenia gravis. The relatively low affinity of VACC for aminoglycosides prompted us to explore alternative mechanisms. We hypothesized that the presynaptic Ca2+-sensing receptor (CaSR) may contribute to aminoglycoside-induced weakness due to its role in modulating synaptic transmission and its sensitivity to aminoglycosides in heterologous expression systems. We have previously shown that presynaptic CaSR controls a non-selective cation channel (NSCC) that regulates nerve terminal excitability and transmitter release. Using direct, electrophysiological recording, we report that neuronal VACCs are inhibited by neomycin (IC50 830 ± 110 μM) at a much lower affinity than CaSR-modulated NSCC currents recorded from acutely isolated presynaptic terminals (synaptosomes; IC50 20 ± 1 μM). Thus, at clinically relevant concentrations, aminoglycoside-induced weakness is likely precipitated by enhanced CaSR activation and subsequent decrease in terminal excitability rather than through direct inhibition of VACCs themselves.

AB - Administration of aminoglycoside antibiotics can precipitate sudden, profound bouts of weakness that have been attributed to block of presynaptic voltage-activated calcium channels (VACCs) and failure of neuromuscular transmission. This serious adverse drug reaction is more likely in neuromuscular diseases such as myasthenia gravis. The relatively low affinity of VACC for aminoglycosides prompted us to explore alternative mechanisms. We hypothesized that the presynaptic Ca2+-sensing receptor (CaSR) may contribute to aminoglycoside-induced weakness due to its role in modulating synaptic transmission and its sensitivity to aminoglycosides in heterologous expression systems. We have previously shown that presynaptic CaSR controls a non-selective cation channel (NSCC) that regulates nerve terminal excitability and transmitter release. Using direct, electrophysiological recording, we report that neuronal VACCs are inhibited by neomycin (IC50 830 ± 110 μM) at a much lower affinity than CaSR-modulated NSCC currents recorded from acutely isolated presynaptic terminals (synaptosomes; IC50 20 ± 1 μM). Thus, at clinically relevant concentrations, aminoglycoside-induced weakness is likely precipitated by enhanced CaSR activation and subsequent decrease in terminal excitability rather than through direct inhibition of VACCs themselves.

KW - Aminoglycoside

KW - Calcium-sensing receptor

KW - GPCR

KW - Myastheia gravis

KW - Nerve terminal

KW - VACC

UR - http://www.scopus.com/inward/record.url?scp=69649104730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69649104730&partnerID=8YFLogxK

U2 - 10.1016/j.neuropharm.2009.07.031

DO - 10.1016/j.neuropharm.2009.07.031

M3 - Article

C2 - 19646457

AN - SCOPUS:69649104730

VL - 57

SP - 502

EP - 505

JO - Neuropharmacology

JF - Neuropharmacology

SN - 0028-3908

IS - 5-6

ER -